Genzyme lands $345M acquisition of Bioenvision

Genzyme is laying claim to the keys to Bioenvision after winning shareholders' approval of the $345 million buyout. SCO Capital Partners, which owns 13 percent of Bioenvision, had fought the deal, saying that the bid undervalued the company. That argument failed to sway a majority of shareholders, though, who are getting $5.60 a share. Genzyme walks away with all the rights to the cancer drug clofarabine, which it co-developed with Bioenvision.

- take a look at the release
- read the report from the International Herald Tribune

Related Articles:
Bioenvision shareholders shun Genzyme takeover bid. Report
Who's next on the biotech buyout hit list? Report
Genzyme wins bidding war for AnorMED. Report
Boston officials herald big Genzyme expansion. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.